Stockreport

Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hyper...

Galectin Therapeutics Inc.  (GALT) 
Last galectin therapeutics inc. earnings: 11/12 08:00 am Check Earnings Report
PDF Data and Safety Monitoring Board (DSMB) recommends the continuation, without modifications, of the adaptive Phase 2b/3 NAVIGATE study of belapectin in metabolic dysfunct [Read more]